Symptom Inventory for Gastrointestinal Stromal Tumors
NCT01178307 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 187
Last updated 2020-01-13
Summary
The goal of this research study is to better understand the symptoms experienced by patients with GIST.
There are 3 parts to this study. In Part 1, participants will complete 1 set of interviews and questionnaires about GIST symptoms. In Part 2, the importance of some symptoms to patients with GIST will be rated by doctors, nurses, patients, and family caregivers. In Part 3, participants will complete questionnaires about GIST symptoms over 1 year.
You are being asked to take part in Part 3 of the study.
Conditions
Interventions
- BEHAVIORAL
-
Questionnaires
10 minutes to complete 3 questionnaires for development of MDASI-GIST
- BEHAVIORAL
-
Interview
Each interview will take approximately 30 minutes.
- BEHAVIORAL
-
MDASI-GIST Questionnaire
Every 4 weeks for one year
Sponsors & Collaborators
- collaborator INDUSTRY
-
M.D. Anderson Cancer Center
lead OTHER
Principal Investigators
-
Loretta A. Williams, PhD, MSN · M.D. Anderson Cancer Center
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-07-29
- Primary Completion
- 2020-07-31
- Completion
- 2020-07-31
Countries
- United States
Study Locations
More Related Trials
-
Ripretinib in Chinese Patients With Advanced GIST: a Real World Study
NCT05697107 ·Status: UNKNOWN
-
Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence
NCT02009423 ·Status: TERMINATED ·Phase: PHASE3
-
A Multi-omics-based Metabolic Typing Study of Gastric Cancer
NCT06134011 ·Status: ACTIVE_NOT_RECRUITING
-
Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis
NCT06109805 ·Status: COMPLETED
-
Biomarker Study of PDR001 in Combination With MCS110 in Gastric Cancer
NCT03694977 ·Status: UNKNOWN ·Phase: PHASE2
-
Predicting Biomarker of Gastric Cancer Chemotherapy Response
NCT03253107 ·Status: RECRUITING
-
Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada
NCT06361576 ·Status: COMPLETED
-
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
NCT00633295 ·Status: COMPLETED ·Phase: PHASE2
-
Resistance to Immunotherapy in Gastric Cancer
NCT03614013 ·Status: UNKNOWN
-
First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
NCT06727981 ·Status: RECRUITING
-
Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer
NCT05497739 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GC
NCT04638959 ·Status: UNKNOWN
-
DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)
NCT04276415 ·Status: TERMINATED ·Phase: PHASE1
-
Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors
NCT00568750 ·Status: COMPLETED ·Phase: PHASE2
-
Prospective Evaluation and Molecular Profiling in People With Gastric Tumors
NCT03027427 ·Status: COMPLETED
-
InteGRAtive Analysis of TuMor, Microenvironment, ImmunitY and Patient Expectation for Personalized Response Prediction in Gastric Cancer
NCT04842916 ·Status: RECRUITING
-
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
NCT00385203 ·Status: COMPLETED ·Phase: PHASE2
-
Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy
NCT06202781 ·Status: RECRUITING
-
Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK
NCT00976612 ·Status: COMPLETED
-
Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)
NCT01270893 ·Status: WITHDRAWN ·Phase: PHASE2
-
The Association Between Microplastics and Macrogenomics and Metabolomics in Gastric Cancer
NCT06856382 ·Status: ACTIVE_NOT_RECRUITING
-
Drug Sensitivity Screening for Gastrointestinal Cancer
NCT04298489 ·Status: UNKNOWN ·Phase: NA
-
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
NCT00397904 ·Status: COMPLETED ·Phase: PHASE2
-
Nutrition-support-team Based Intervention in Patients With Advanced Gastrointestinal Cancer
NCT03631537 ·Status: UNKNOWN ·Phase: NA
-
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
NCT00061932 ·Status: COMPLETED ·Phase: PHASE2